Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$108.18 USD

108.18
1,175,736

-0.51 (-0.47%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $108.25 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances.

Baxter (BAX) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.

What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.

Company News for Apr 6, 2022

by Zacks Equity Research

Companies In The News Are: ZBH, CCL, UNH, CHNG, BA.

Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage

by Zacks Equity Research

Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.

Zimmer Biomet (ZBH) New WalkAI Model to Bolster Robotics Arm

by Zacks Equity Research

WalkAI adds powerful predictive analytic capabilities to ZBEdge, Zimmer Biomet's (ZBH) suite of integrated digital and robotic technologies.

Zimmer (ZBH) Down 3.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe

by Zacks Equity Research

According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.

Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore

by Zacks Equity Research

Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.

Zimmer Biomet (ZBH) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

According to Zimmer Biomet (ZBH), both Q4 net sales and earnings metrics are negatively impacted by China VBP in Knees, Hips and S.E.T. product categories.

Zimmer Biomet (ZBH) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of -0.51% and 0.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.

Smith+Nephew (SNN) to Acquire Orlando-Based Engage Surgical

by Zacks Equity Research

Smith+Nephew's (SNN) acquisition of Engage Surgical reinforces its growth strategy while expanding its Orthopaedic Reconstruction product line.

Abbott (ABT) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 11.86% and 8.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet's (ZBH) Pandemic Recovery Slow, Margin Woes Stay

by Zacks Equity Research

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

Urmimala Biswas headshot

Forget Zimmer Biomet (ZBH), Buy These 3 Medical Devices Stocks

by Urmimala Biswas

With orthopedic stocks like Zimmer Biomet (ZBH) are grappling with several issues, it is wise to invest in medical device stocks like TMO, NEOG and CERN instead for 2022.

Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic

by Zacks Equity Research

Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.

New Strong Sell Stocks for December 6th

by Zacks Equity Research

BYND, NVST, FSTR, ZBH, and PHR have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2021.

Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic

by Zacks Equity Research

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

New Strong Sell Stocks for November 9th

by Zacks Equity Research

MGLN, SAND, UFCS, WW, and ZBH have been added to the Zacks Rank #5 (Strong Sell) List on November 9, 2021.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed

by Zacks Equity Research

Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.

Zimmer Biomet (ZBH) Beats Q3 Earnings Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 3.43% and -1.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products' Nov 4 Earnings Roster: BDX, ZBH & More

by Trina Mukherjee

The Medical Product companies' Q3 results are likely to reflect huge adoption of their COVID-related support products. Let's see how BDX, ZBH, ABC and XRAY are poised ahead of their earnings releases.